CAJ | 학술논문

目的:评估拉坦前列素,曲伏前列素和比马前列素在挪威,瑞典及丹麦(斯堪的纳维亚)治疗开角型青光眼的成本效用.方法:建立马尔可夫卫生经济学决策分析模型,评估比较前列腺素类似物的成本效用.健康状态为稳定及进展期青光眼.原发性开角型青光眼和表皮剥脱性青光眼的转换概率均由发表的医学文献数据计算所得.通过对分散遍及于各国家的45位眼科医生进行调查获得临床医疗模式.各国家的具体单位成本包括药费,就诊费,诊断及治疗费.生命质量权重值指定为视力 0.50～0.84,时间范围为5a.所有分析均为付款人观点成本效益分析,成本结果每年降低3%.结果:在挪威和瑞典,拉坦前列素较曲伏前列素和比马前列素费用低而效益高,拉坦前列素比其他药物费用低达4%.在丹麦,所有三种药物的费用在彼此的1.5%之内,比马前列素与曲伏前列素费用相当,而较拉坦前列素费用略低,但是拉坦前列素较曲伏前列素和比马前列素效益高.各国家所有药物的效用在一个窄范围内.结论:在斯堪的纳维亚,拉坦前列素为其他可买到的前列腺素类似物提供了经济有效的替代物.
목적:평고랍탄전렬소,곡복전렬소화비마전렬소재나위,서전급단맥(사감적납유아)치료개각형청광안적성본효용.방법:건립마이가부위생경제학결책분석모형,평고비교전렬선소유사물적성본효용.건강상태위은정급진전기청광안.원발성개각형청광안화표피박탈성청광안적전환개솔균유발표적의학문헌수거계산소득.통과대분산편급우각국가적45위안과의생진행조사획득림상의료모식.각국가적구체단위성본포괄약비,취진비,진단급치료비.생명질량권중치지정위시력 0.50～0.84,시간범위위5a.소유분석균위부관인관점성본효익분석,성본결과매년강저3%.결과:재나위화서전,랍탄전렬소교곡복전렬소화비마전렬소비용저이효익고,랍탄전렬소비기타약물비용저체4%.재단맥,소유삼충약물적비용재피차적1.5%지내,비마전렬소여곡복전렬소비용상당,이교랍탄전렬소비용략저,단시랍탄전렬소교곡복전렬소화비마전렬소효익고.각국가소유약물적효용재일개착범위내.결론:재사감적납유아,랍탄전렬소위기타가매도적전렬선소유사물제공료경제유효적체대물.
AIM: To evaluate the cost-effectiveness of latanoprost, travoprost and bimatoprost monotherapy in open angle glaucoma in Norway, Sweden and Denmark(Scandinavia). METHODS: A Markov decision-analytic health economic model was developed to estimate the comparative cost-effectiveness of prostaglandin analogs. Health states were stable and progressed glaucoma. Transition probabilities for both primary open angle and exfoliation glaucoma were populated with data from published medical literature. Clinical practice patterns were derived from surveys obtained from 45 ophthalmologists dispersed throughout each country. Specific unit costs for each country were used for medications, clinic visits, diagnostics and therapies. Quality-of-life weights were assigned for visual acuity from 0. 50- 0. 84. The time horizon was five years. All analyses were from a payer perspective and cost results were discounted at 3% per annum.RESULTS: Latanoprost was less expensive and more effective than bimatoprost and travoprost in both Norway and Sweden. Latanoprost was up to 4% less expensive in Sweden and Norway and the costs of all three medicines were within 1.5% of each other in Denmark. In Denmark bimatoprost dominated travoprost and was slightly less expensive than latanoprost while latanoprost was more effective than bimatoprost or travoprost. Effectiveness was within a narrow range for all products in each country.CONCLUSION: Latanoprost provides a cost-effective alternative to other available prostaglandin analogs in Scandinavia.